Efficacy outcomes with InO or SC by select genomic alterations. (A) Across genomic alterations, there was a potential for response to InO treatment, and CR/CRi rates were significantly higher in patients with TP53 alterations who received InO. (B) A trend toward a PFS benefit was observed across genomic alterations; however, (C) no such trend was observed for OS. ^aAll patients bearing an alteration in a gene with an overall alteration prevalence n of at least 8; ^bCIs were approximated using nominal distribution when ≥5 patients were in both the CR/CRi and non–CR/CRi subgroups. Where <5 patients were in either subgroup, exact method was used.